Cue Biopharma to Host Business Update Call and Webcast
Cue Biopharma to Host Business Update Call and Webcast
BOSTON, April 02, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively modulate disease-specific T cells, announced today that it will host a conference call and webcast to provide a business update on Monday, April 8, 2024 at 4:30 p.m. EDT. Live and archived versions of the event can be accessed via the Company's website.
波士顿，2024年4月2日（GLOBE NEWSWIRE）——Cue Biopharma, Inc.（纳斯达克股票代码：CUE）是一家处于临床阶段的生物制药公司，正在开发一种用于选择性调节疾病特异性T细胞的新型治疗生物制剂。该公司今天宣布，将在美国东部时间2024年4月8日星期一下午4点30分举办电话会议和网络直播，提供业务最新情况。该活动的直播和存档版本可通过公司网站访问。
The Company will provide a corporate update highlighting measurable progress advancing its lead clinical oncology programs, CUE-101 and CUE-102, its lead preclinical autoimmune program CUE-401 partnered with Ono Pharmaceutical, as well as additional autoimmune pipeline developments and business updates.
该公司将提供公司最新情况，重点介绍其主要临床肿瘤学项目 CUE-101 和 CUE-102、与小野制药合作的主要临床前自身免疫项目 CUE-401 的进展情况，以及其他自身免疫产品线开发和业务最新情况。
Webcast Details
网络直播详情
| Monday, April 8 at 4:30 p.m. EDT | |
| Investors: | 1-888-886-7786 |
| International Investors: | 1-416-764-8658 |
| Conference ID: | 02444369 |
| Request a return call via the Call me link: | |
| Participants can use guest dial-in numbers above and be answered by an operator OR click the Call me link for instant telephone access to the event. The link will be active 15 minutes prior to the scheduled start time. | |
| Webcast: | |
| 美国东部时间 4 月 8 日星期一下午 4:30 | |
| 投资者： | 1-888-886-7786 |
| 国际投资者： | 1-416-764-8658 |
| 会议编号： | 02444369 |
| 通过 “给我打电话” 链接申请回电： | |
| 参与者可以使用上面的访客拨入号码由接线员接听，或者单击 “给我打电话” 链接以即时通过电话访问活动。该链接将在预定开始时间前 15 分钟处于活动状态。 | |
| 网络直播： | |
About Cue Biopharma
Cue Biopharma, a clinical-stage biopharmaceutical company, is developing a novel class of injectable biologics to selectively engage and modulate disease-specific T cells directly within the patient's body. The company's proprietary platform, Immuno-STAT (Selective Targeting and Alteration of T cells) and biologics are designed to harness the curative potential of the body's intrinsic immune system through the selective modulation of disease-specific T cells without the adverse effects of broad systemic immune modulation.
Cue Biopharma
临床阶段的生物制药公司Cue Biopharma正在开发一类新型的可注射生物制剂，用于直接在患者体内选择性地参与和调节疾病特异性T细胞。该公司的专有平台Immuno-Stat （选择性靶向和改变 T 细胞） 生物制剂旨在通过选择性调节疾病特异性T细胞来利用人体内在免疫系统的治疗潜力，而不会受到广泛的全身免疫调节的不利影响。
Headquartered in Boston, Massachusetts, we are led by an experienced management team and independent Board of Directors with deep expertise in immunology and immuno-oncology as well as the design and clinical development of protein biologics.
我们总部位于马萨诸塞州波士顿，由经验丰富的管理团队和独立董事会领导，他们在免疫学和免疫肿瘤学以及蛋白生物制剂的设计和临床开发方面拥有深厚的专业知识。
For more information please visit and follow us on X (Twitter) and LinkedIn.
欲了解更多信息，请访问并在 X（推特）和 LinkedIn 上关注我们。
Investor Contact
Marie Campinell
Senior Director, Corporate Communications
Cue Biopharma, Inc.
mcampinell@cuebio.com
投资者联系人
玛丽·坎皮内尔
企业传播高级董事
Cue Biopharma, Inc.
mcampinell@cuebio.com
Media Contact
Jonathan Pappas
LifeSci Communications
jpappas@lifescicomms.com
媒体联系人
乔纳森·帕帕斯
LifeSci
jpappas@lifescicomms.com